Dermatofibrosarcoma protuberans
ICD-10 C49.9 · ICD-11 2B53.Y

Treatment of Dermatofibrosarcoma Protuberans When Unresectable, Borderline Resectable, or When Surgery Would Cause Unacceptable Outcomes

Clinical Scenario

This protocol addresses dermatofibrosarcoma protuberans (DFSP) in patients where the tumor is unresectable or borderline resectable, or where achieving negative surgical margins would result in unacceptable functional or cosmetic outcomes.

Approach

In this setting, tumor mutation analysis is a relevant consideration alongside a neoadjuvant systemic therapy option.

The complete regimen, sequencing, and clinical decision pathway are available in the full structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

For unresectable/borderline resectable disease, consider tumor mutation analysis and neoadjuvant Imatinib

Consider neoadjuvant Imatinib for patients in whom resection with negative margins may result in unacceptable functional or cosmetic outcomes.

Additionally, tumor mutation analysis and neoadjuvant imatinib can be considered options for unresectable or borderline resectable disease.

View source ↗